Evidence map›Paper›PMID 38068487›Full record

ArticleJournal of clinical medicine2023

The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data.

Christian Wolfram, Norbert Pfeiffer, Tobias Hudde, Alexander Klatt, Birthe Schnegelsberg, Mike Ross, Focke Ziemssen, Alexander K Schuster

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Opportunities to Improve Management of Neovascular Age-related Macular Degeneration: Communication at Diagnosis and Beyond : Insights from the German nAMD Barometer Survey.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Christian WolframDepartment of Ophthalmology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Norbert PfeifferDepartment of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Tobias HuddeEye Hospital Wolfsburg-Fallersleben, Am Spieker 10, 38440 Wolfsburg, Germany.
Alexander KlattEye Center Klatt, Henry-Wetjen-Platz 3, 28844 Weyhe, Germany.
Birthe SchnegelsbergNovartis Pharma GmbH, Roonstr. 25, 90429 Nuremberg, Germany.
Mike RossNovartis Pharma GmbH, Roonstr. 25, 90429 Nuremberg, Germany.
Focke ZiemssenDepartment of Ophthalmology, Leipzig University Hospital, University of Leipzig, Liebigstraße 12, Haus 1, 04109 Leipzig, Germany.ORCID 0000-0002-3873-0581
Alexander K SchusterDepartment of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Johannes Gutenberg University Mainz · DENovartis (Germany) · DEFraunhofer Project Centre Wolfsburg · DESTZ eyetrial · DEUniversität Hamburg · DEUniversity Hospital Leipzig · DE

Funding

Novartis Pharma, Nuremberg, Germany 0000 not able to provide a grant number at the moment
6 · The paper itself

Abstract

backgroundRetinal diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or branch/central retinal vein occlusion (B/CRVO) have significant implications for patients' social and psychological well-being. The ALBATROS study aimed to assess the care situation of patients who received anti-VEGF (vascular endothelial growth factor) treatment. To gain a comprehensive understanding of patients' backgrounds and attitudes, we developed an exploratory, structured questionnaire, the Basic Care and Patient Satisfaction Questionnaire (BPZ-9).

methodsThe data collection took place at the beginning and after twelve months of anti-VEGF therapy. The BPZ-9 questionnaire comprises nine questions to evaluate patients' psychological and social situation and satisfaction with treatment.

resultsData were collected from 1478 nAMD (mean 78 years), 445 DME (67 years), 233 BRVO (70 years), and 144 CRVO (71 years) patients at 102 study centers throughout Germany. One in four patients had difficulties walking, and one in five needed an accompanying person for treatment. Anxiety about losing vision was present in three out of four patients at the beginning, and it slightly decreased to two out of three patients over the 12-month treatment period. The distress of having a retinal disease was generally higher than the distress related to the treatment. Most patients reported high treatment satisfaction (73%) and felt well-informed (81%).

conclusionsThere is a relevant social and psychological impact related to anti-VEGF treatment. The patients' perception, attitudes, and commitment need further investigation.

Indexed as

anti-VEGFattitudeblindnessfearhealth carepatient perspectivepsychologyvision loss

Identifiers

PMID38068487
PMCPMC10707522
OpenAlexW4389206964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.